| Robert Riederman, MD | |
|
2700 Quarry Lake Dr, Suite 300, Baltimore, MD 21209-2230 | |
| (410) 377-8900 | |
| (410) 377-3156 |
| Full Name | Robert Riederman |
|---|---|
| Gender | Male |
| Speciality | Sports Medicine |
| Experience | 41 Years |
| Location | 2700 Quarry Lake Dr, Baltimore, Maryland |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1376532267 | NPI | - | NPPES |
| 532261800 | Medicaid | MD | |
| 532261800. | Medicaid | MD |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207X00000X | Orthopaedic Surgery | D38150 (Maryland) | Primary |
| 207XX0005X | Orthopaedic Surgery - Sports Medicine | D38150 (Maryland) | Secondary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Centers For Advanced Orthopaedics Llc | 8123260981 | 476 |
News Archive
Neurodegenerative disorders such as Alzheimer's disease are typically characterized by protein deposits in the brain. These are comprised of defective, insoluble proteins which no longer fulfill their function and which cells are unable to break down. The work group headed by Professor Christian Behl of the Institute of Pathobiochemistry of the University Medical Center of Johannes Gutenberg University Mainz has determined the RAB3GAP complex as a novel factor that influences the efficient degradation of proteins.
Embryonic stem cell therapies have been proposed for regenerative medicine and tissue replacement after injury or disease.
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
According to the National Heart, Lung and Blood Institute, the average sleep apnea sufferer stops breathing and loses oxygen between five and 30 times a night. This lack of oxygen leads to a host of complications, including high blood pressure, vascular disease, an abnormal heart rhythm, or even a fatal cardiac event. Now, a team of University of Missouri researchers is exploring the changes in distinct brain regions that contribute to these symptoms in hopes of combating this common health issue.
› Verified 3 days ago
| Entity Name | Centers For Advanced Orthopaedics Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1487093167 PECOS PAC ID: 8123260981 Enrollment ID: O20130808000102 |
News Archive
Neurodegenerative disorders such as Alzheimer's disease are typically characterized by protein deposits in the brain. These are comprised of defective, insoluble proteins which no longer fulfill their function and which cells are unable to break down. The work group headed by Professor Christian Behl of the Institute of Pathobiochemistry of the University Medical Center of Johannes Gutenberg University Mainz has determined the RAB3GAP complex as a novel factor that influences the efficient degradation of proteins.
Embryonic stem cell therapies have been proposed for regenerative medicine and tissue replacement after injury or disease.
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
According to the National Heart, Lung and Blood Institute, the average sleep apnea sufferer stops breathing and loses oxygen between five and 30 times a night. This lack of oxygen leads to a host of complications, including high blood pressure, vascular disease, an abnormal heart rhythm, or even a fatal cardiac event. Now, a team of University of Missouri researchers is exploring the changes in distinct brain regions that contribute to these symptoms in hopes of combating this common health issue.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Robert Riederman, MD 2700 Quarry Lakedr, Suite 300, Baltimore, MD 21209-2230 Ph: (410) 377-8900 | Robert Riederman, MD 2700 Quarry Lake Dr, Suite 300, Baltimore, MD 21209-2230 Ph: (410) 377-8900 |
News Archive
Neurodegenerative disorders such as Alzheimer's disease are typically characterized by protein deposits in the brain. These are comprised of defective, insoluble proteins which no longer fulfill their function and which cells are unable to break down. The work group headed by Professor Christian Behl of the Institute of Pathobiochemistry of the University Medical Center of Johannes Gutenberg University Mainz has determined the RAB3GAP complex as a novel factor that influences the efficient degradation of proteins.
Embryonic stem cell therapies have been proposed for regenerative medicine and tissue replacement after injury or disease.
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
According to the National Heart, Lung and Blood Institute, the average sleep apnea sufferer stops breathing and loses oxygen between five and 30 times a night. This lack of oxygen leads to a host of complications, including high blood pressure, vascular disease, an abnormal heart rhythm, or even a fatal cardiac event. Now, a team of University of Missouri researchers is exploring the changes in distinct brain regions that contribute to these symptoms in hopes of combating this common health issue.
› Verified 3 days ago
Robert J Brumback, MD Orthopedic Surgery Medicare: Not Enrolled in Medicare Practice Location: 3333 North Calvert Street, Suite 400, Baltimore, MD 21218 Phone: 410-554-2270 Fax: 410-261-2726 | |
Dr. Milford Howarth Marchant Jr., M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 2900 S Hanover St, Baltimore, MD 21225 Phone: 410-350-8336 Fax: 410-350-7178 | |
Dr. Michelle Ghert, MD Orthopedic Surgery Medicare: Not Enrolled in Medicare Practice Location: 110 S Paca St Fl 6, Baltimore, MD 21201 Phone: 614-397-2721 | |
Henry R Boucher, MD Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 3333 North Calvert Street, Suite 400, Baltimore, MD 21218 Phone: 410-554-2270 Fax: 410-261-2726 | |
John J Carbone, M.D. Orthopedic Surgery Medicare: Not Enrolled in Medicare Practice Location: 3001 S Hanover St, Gruehn Bldg, Ste 502, Baltimore, MD 21225 Phone: 410-350-8300 | |
Dr. Dawn Laporte, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 601 N Caroline St, Rm 5210, Baltimore, MD 21287 Phone: 410-955-3134 | |
Paul C Mcafee, M.D., MBA Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 3333 N Calvert St Ste 655, Baltimore, MD 21218 Phone: 410-554-2175 Fax: 410-554-2917 |